Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone
Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone
复制标题
DOI：
10.21873/anticanres.15047
复制
发表时间：
2021-05-01
影响因子：
2
通讯作者：
Hattori, Noboru
中科院分区：
文献类型：
--
作者：
Masuda, Takeshi;Wakabayashi, Yu;Hattori, Noboru
背景/目的：表皮生长因子受体（EGFR）突变在未经治疗的非小细胞肺癌（NSCLC）患者中的意义仍不确定。我们旨在确定EGFR突变在仅接受最佳支持治疗（BSC）的患者中的意义，并比较仅EGFR酪氨酸激酶抑制剂（TKI）治疗与BSC患者的结局。患者和方法：1991年4月至2018年8月期间，我们机构的1，197例诊断为不可切除NSCLC的患者入组了本研究。结果如下：在226例接受EGFR突变分析并单独接受BSC的患者中，35例和191例携带突变，这些组之间的中位生存时间（MST）没有显著差异。仅EGFR-TKI治疗的患者与EGFR突变的BSC患者的比较显示，前者的MST比后者长3倍。结论：我们的研究结果可能有助于解释EGFR-TKI对直接接受BSC的患者的益处。因此，临床回顾性未经治疗的化疗靶向非新的全身化疗（PS），腺癌激活因子
Background/Aim: The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR-tyrosine kinase inhibitors (TKI)-treated vs. BSC patients. Patients and Methods: Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study. Results: Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKItreated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter. Conclusion: Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC. Lung worldwide underwent those Accordingly, clinical retrospective untreated chemotherapy targeted non new chemotherapy systemic (PS), adenocarcinoma activating factor